NKTR NEKTAR THERAPEUTICS
Pharmaceutical Preparations · Nasdaq · SEC CIK 906709 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-16.6%
TTM net income YoY-46.8%
TTM EPS YoY18.0%
Revenue 3-yr CAGR-16.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-319.8%
Net margin-339.7%
FCF margin-493.4%
EBITDA margin-318.5%
Returns
ROE-37.9%
ROA-26.5%
ROIC (approx.)-30.7%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets18.1%
Debt / equity0.00x
Current ratio9.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.45x
Accruals ratio11.9%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.39M | $10.13M | $10.86M | $21.81M | $11.79M | $11.18M | $10.46M | $29.18M |
| Cost of revenue | — | — | — | $0 | $0 | $0 | $0 | $7.98M |
| Gross profit | — | — | — | $21.81M | $11.79M | $11.18M | $10.46M | $21.20M |
| R&D expense | $44.12M | $39.13M | $35.68M | $29.71M | $27.25M | $29.89M | $30.48M | $28.75M |
| SG&A expense | $24.57M | $12.77M | $13.44M | $11.19M | $16.07M | $17.07M | $24.35M | $17.14M |
| Operating income | -$57.80M | -$42.34M | -$39.05M | -$27.66M | -$31.67M | -$36.23M | -$44.53M | $14.35M |
| Pretax income | -$55.05M | -$40.30M | -$43.09M | -$43.43M | -$35.02M | -$39.40M | -$46.37M | $7.00M |
| Income tax | $22,000 | $2,000 | $64,000 | $31,000 | -$33,000 | -$188,000 | $52,000 | -$259,000 |
| Net income | -$55.65M | -$40.62M | -$44.90M | -$36.08M | -$35.52M | -$41.59M | -$50.88M | $7.26M |
| EBITDA | -$57.63M | -$42.19M | -$38.90M | -$27.48M | -$31.48M | -$36.02M | -$44.11M | $14.39M |
| EPS (basic) | -1.63 | -1.23 | -1.82 | — | -1.87 | -2.95 | -3.62 | — |
| EPS (diluted) | -1.63 | -1.23 | -1.82 | — | -1.87 | -2.95 | -3.62 | — |
| Weighted avg. shares (diluted) | 34.18M | 33.05M | 24.74M | — | 18.95M | 14.09M | 14.06M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $34.69M | $39.27M | $149.58M | $15.12M | $41.03M | $42.99M | $38.89M | $44.25M |
| Short-term investments | $579.67M | $645.07M | $419.03M | $230.64M | $229.18M | $132.91M | $179.74M | $210.97M |
| Receivables | — | — | — | — | — | — | — | $0 |
| Inventory | — | — | — | $0 | — | — | — | $0 |
| Current assets | $679.33M | $739.40M | $589.04M | $266.27M | $281.36M | $186.57M | $229.91M | $261.29M |
| PP&E, net | — | — | — | $2.06M | $2.83M | $2.99M | $3.16M | $3.41M |
| Total assets | $1.04B | $1.10B | $763.27M | $280.41M | $301.35M | $207.53M | $256.24M | $303.85M |
| Current liabilities | $75.48M | $70.98M | $57.71M | $53.54M | $66.34M | $71.39M | $70.93M | $61.40M |
| Total liabilities | $187.53M | $192.01M | $187.06M | $190.57M | $216.26M | $231.75M | $242.50M | $243.11M |
| Shareholders' equity | $849.72M | $903.12M | $576.22M | $89.83M | $85.09M | -$24.21M | $13.74M | $60.74M |
| Shares outstanding | 34.21M | 20.38M | 20.38M | 20.38M | 19.65M | 12.46M | 186.10M | 12.39M |
| Cash flow statement | ||||||||
| Operating cash flow | -$71.93M | -$75.77M | -$44.30M | -$64.96M | -$48.76M | -$45.74M | -$49.05M | -$46.19M |
| Capital expenditure | $398,000 | $94,000 | $18,000 | $18,000 | $114,000 | $37,000 | $2,000 | $459,000 |
| Free cash flow | -$72.33M | -$75.86M | -$44.32M | -$64.98M | -$48.88M | -$45.77M | -$49.05M | -$46.65M |
| Investing cash flow | $66.90M | -$399.11M | -$350.79M | $372,000 | -$94.87M | $49.62M | $43.69M | $60.21M |
| Financing cash flow | $448,000 | $364.57M | $529.55M | $38.67M | $141.68M | $211,000 | $7,000 | $83,000 |
| Depreciation & amortization | $169,000 | $156,000 | $151,000 | $190,000 | $196,000 | $214,000 | $426,000 | $41,000 |
| Stock-based compensation | $3.75M | $3.37M | $3.35M | $2.19M | $3.07M | $3.49M | $3.90M | $4.80M |
| Share buybacks | — | — | — | $0 | $0 | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.